全文获取类型
收费全文 | 335篇 |
免费 | 14篇 |
国内免费 | 6篇 |
专业分类
儿科学 | 18篇 |
基础医学 | 26篇 |
口腔科学 | 17篇 |
临床医学 | 46篇 |
内科学 | 113篇 |
皮肤病学 | 16篇 |
神经病学 | 10篇 |
特种医学 | 38篇 |
外科学 | 14篇 |
综合类 | 4篇 |
预防医学 | 21篇 |
眼科学 | 1篇 |
药学 | 18篇 |
肿瘤学 | 13篇 |
出版年
2018年 | 2篇 |
2017年 | 6篇 |
2015年 | 4篇 |
2014年 | 7篇 |
2013年 | 13篇 |
2011年 | 5篇 |
2010年 | 11篇 |
2009年 | 4篇 |
2008年 | 9篇 |
2007年 | 9篇 |
2006年 | 5篇 |
2005年 | 17篇 |
2003年 | 4篇 |
2001年 | 6篇 |
1999年 | 7篇 |
1998年 | 20篇 |
1997年 | 18篇 |
1996年 | 22篇 |
1995年 | 13篇 |
1994年 | 17篇 |
1993年 | 17篇 |
1992年 | 7篇 |
1991年 | 4篇 |
1990年 | 5篇 |
1989年 | 8篇 |
1988年 | 11篇 |
1987年 | 10篇 |
1986年 | 8篇 |
1985年 | 9篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1981年 | 4篇 |
1980年 | 8篇 |
1979年 | 5篇 |
1978年 | 4篇 |
1977年 | 11篇 |
1976年 | 7篇 |
1975年 | 4篇 |
1974年 | 4篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1970年 | 1篇 |
1966年 | 1篇 |
1959年 | 2篇 |
1954年 | 1篇 |
1949年 | 1篇 |
1939年 | 1篇 |
1931年 | 1篇 |
1919年 | 1篇 |
1889年 | 1篇 |
排序方式: 共有355条查询结果,搜索用时 15 毫秒
1.
2.
3.
Alveolar Retention and Clearance of Insoluble Particles in Rats Simulated by a New Physiology-Oriented Compartmental Kinetics Model 总被引:1,自引:0,他引:1
Alveolar Retention and Clearance of Insoluble Particles in RatsSimulated by a New Physiology-Oriented Compartmental KineticsModel. STOBER, W., MORROW, P. E., AND MORAWIETZ, G. (1990).Fundam Appl. Toxtcol. 15,329349. A physiology-orientedcompartmental kinetics model of alveolar retention of inhaledinsoluble paniculate matter in rat lungs was proposed in a recentpaper, (W. Stober, P. E. Morrow, and M. D. Hoover, 1989, Fundam.Appl. Toxicol. 13, 823843), and the retention patternsobtained with the model for a hypothetical set of input dataappeared to simulate phenomena which were observed in inhalationstudies with Fischer 344 rats. The present paper representsthe results of applying the new model for simulations of theactual experimental retention data of five different inhalationstudies with Fischer 344 rats exposed to three different materials.The experimental data showed that model adjustments had to bemade in order to account for clearance effects that appearedto be influenced by the age of the animals. After these adjustmentswere made and an appropriate set of values for the model parametersdescribing the respective exposure conditions was used, themodel was constrained to represent the empirical data of allof the studies by one unique set of parameter values. Changesin particular values of this set were considered to be acceptableonly if they reflected changes of relevant properties of theinhaled paniculate matter. The final simulations did not completelycomply with this self-imposed criterion. However, the degreeof compliance and the simulation quality achieved with a minimumof parameter variations seem to be unprecedented in retentionmodeling. The results of the study encourage attempts for furtherrefining the present model 相似文献
4.
5.
6.
Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia 总被引:1,自引:1,他引:1
Robinson N; Sanders JE; Benyunes MC; Beach K; Lindgren C; Thompson JA; Appelbaum FR; Fefer A 《Blood》1996,87(4):1249-1254
Allogeneic bone marrow transplantation (BMT) for advanced acute leukemia is associated with a high risk of relapse. It is postulated that interleukin-2 (IL-2) administered after BMT might induce or amplify a graft-versus-leukemia effect and thereby reduce the relapse rate. To identify an IL-2 regimen for testing this hypothesis, a phase I trial of IL-2 (Roche) was performed in children in complete remission (CR) without active graft-versus-host disease (GVHD) off immunosuppressive agents after unmodified allogeneic matched-sibling BMT for acute leukemia beyond first remission. Beginning a median of 68 days after BMT, 17 patients received escalating doses of induction IL-2 (0.9, 3.0, or 6.0 x 10(6) IU/m2/d representing levels I, II, and III) for 5 days by continuous intravenous infusion (CIV). After 6 days of rest, they received maintenance IL-2 (0.9 x 10(6) IU/m2/d) for 10 days by CIV infusion. Levels I and II were well-tolerated, but, of 6 patients at level III, 1 developed pulmonary infiltrates, 1 developed hypotension (both resolved), and 1 died of bacterial sepsis and acute respiratory distress syndrome. Grade II acute GVHD developed in 1 patient at level I and 1 at level III. The maximum tolerated dose of induction IL-2 was level II. IL-2 induced lymphocytosis, with an increase in CD56+ and CD8+ cells. Ten patients remain in CR at 5+ to 67+ months. Thus, a regimen of IL-2 has been identified that did not induce a high incidence of acute GVHD when administered to children after unmodified allogeneic BMT. Its clinical activity will be assessed in a phase II trial. 相似文献
7.
Bensinger WI; Weaver CH; Appelbaum FR; Rowley S; Demirer T; Sanders J; Storb R; Buckner CD 《Blood》1995,85(6):1655-1658
Peripheral blood stem cells (PBSCs) are widely used in autologous transplantation because of ease of collection and rapid hematopoietic reconstitution. However, PBSCs have rarely been used for allogeneic transplantation because of concerns about donor toxicities from cytokine administration and the theoretical increased risk of graft- versus-host-disease (GVHD) from the large number of T cells infused. Eight patients with advanced malignancies received allogeneic PBSC transplants from genotypically HLA-identical sibling donors. All donors received 5 days of recombinant human granulocyte colony-stimulating factor (rhG-CSF; 16 micrograms/kg/day) subcutaneously and were leukapheresed for 2 days. After treatment of the patient with total body irradiation and cyclophosphamide (n = 7) or etoposide, thiotepa, and cyclophosphamide (n = 1), PBSCs were infused immediately after collection and without modification. All patients received cyclosporine and either methotrexate (n = 6) or prednisone (n = 2) for GVHD prophylaxis, rhG-CSF was well tolerated with mild bone pain requiring acetaminophen occurring in two donors. All patients engrafted and in seven hematopoietic recovery was rapid, with 500 neutrophils/microL achieved by day 18 and 20,000 platelets/microL by day 12. Complete donor engraftment was documented by Y chromosome analysis in all four sex-mismatched donor-recipient pairs tested and by DNA analysis in two sex-matched pairs. One patient died on day 18 of veno-occlusive disease of the liver with engraftment but before chromosome analysis could be performed (results are pending in 1 patient). A second patient died of fungal infection 78 days after transplant. Grade 2 acute GVHD occurred in two patients and grade 3 GVHD occurred in one patient. One patient is 301 days from transplant in remission with chronic GVHD; the remaining five patients are alive and disease free 67 to 112 days after transplantation. Preliminary results indicate that allogeneic PBSCs mobilized by rhG-CSF can provide rapid hematologic recovery without an appreciably greater incidence of acute GVHD than would be expected with marrow. Further follow-up is required to determine the incidence of chronic GVHD and any potential beneficial effects on relapse after transplant. 相似文献
8.
Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation 总被引:16,自引:10,他引:16
Bensinger WI; Clift R; Martin P; Appelbaum FR; Demirer T; Gooley T; Lilleby K; Rowley S; Sanders J; Storb R; Buckner CD 《Blood》1996,88(7):2794-2800
Allogeneic peripheral blood stem cell (PBSC) transplants from HLA- identical siblings were performed in 37 patients with advanced hematologic malignancies. Outcomes were compared to a historical group of 37 similar patients with advanced hematologic malignancies receiving bone marrow (BM) transplants from HLA-identical donors. The PBSC group and historical BM group were well matched for diagnosis, disease stage, age, and graft-versus-host disease (GVHD) prophylaxis. Patients received PBSC transplants between 1993 to 1995 while BM patients were treated between 1989 to 1994. Engraftment, measured by the time to reach a peripheral neutrophil count > 500/L and platelet count > 20,000/microL without transfusions, occurred on days 14 and 11 in the patients transplanted with PBSC compared to days 16 and 15 in the patients receiving BM (P = .00063, .00014). The PBSC group required a median of 8 U of red blood cells and 24 U of platelets compared to 17 U of red blood cells and 118 U of platelets for BM transplant recipients (P = .0005, .0001). The estimated risks of developing grades 2 to 4 acute GVHD were 37% for the PBSC group and 56% for the BM group (P = .18), while the estimated risks of grades 3 to 4 acute GVHD were 14% for the PBSC group and 33% for the BM group, P = .05). Chronic GVHD occurred in 7 of 18 evaluable patients receiving PBSC and 6 of 23 evaluable patients receiving BM, P = .5. The estimated risks of transplant-related mortality at 200 days were 27% versus 45% (P = .33) relapse were 70% versus 53% (P = .27) and of overall survival were 50% and 41% (P = .39) for patients transplanted with PBSC or BM, respectively. This retrospective comparison suggests that compared to marrow transplantation from HLA-identical donors, allogeneic PBSC transplantation from HLA-identical donors is associated with faster engraftment, fewer transfusions, and no greater incidence of acute or chronic GVHD. 相似文献
9.
Two patients with aplastic anemia were treated with high-dose cyclophosphamide and marrow transplantation from their normal, genetically identical twin. Both patients rapidly recovered normal marrow function, but marrow failure recurred 13 and 18 months later. Because donor and host pairs were identical twins, these cases of graft failure could not have resulted from the usual cause of graft failure, ie, immunological reactivity of host cells against unshared minor histocompatibility antigens of the donor. These results imply that there are at least two mechanisms responsible for graft failure after marrow transplantation for severe aplastic anemia. 相似文献
10.
Weaver CH; Buckner CD; Longin K; Appelbaum FR; Rowley S; Lilleby K; Miser J; Storb R; Hansen JA; Bensinger W 《Blood》1993,82(7):1981-1984
Five syngeneic transplants were performed in four patients following myeloablative therapy using unmodified peripheral blood mononuclear cells (PBMCs) collected after the administration of recombinant human granulocyte colony stimulating factor (rhG-CSF) to normal donors. The only toxicity experienced by the four normal donors was bone pain. Four patients received two collections of PBMCs, and a second transplant was performed in one patient with one collection. The patients received a median of 20.53 x 10(8) total nucleated cells/kg (range 20 to 25.5), 11.3 x 10(8) total mononuclear cells/kg (range 6.52 to 17.2), 113.1 x 10(4)/kg CFU-GM (range 46.7 to 211.8) and 9.6 x 10(6) CD34+ cells/kg (range 1.6 to 12.6) Post-transplant growth factors were not administered. The median time to an absolute neutrophil count greater than 0.5 x 10(9)/L was 14 days (range 10 to 18). The median time to platelet transfusion independence was 11 days (range 10 to 13). Two patients had the number of CD3+ T lymphocytes determined in the pheresis product. An average of 3.04 x 10(10) CD3+ cells were collected per pheresis. This represents an approximate 1 log increase over the number of T lymphocytes in a typical bone marrow transplant. Rh-GCSF can be used to mobilize peripheral blood progenitor cells from normal donors with minimal toxicity. Studies of allogeneic transplants using PBMCs collected after rhG-CSF administration to determine permanent grafting ability and the incidence and severity of graft-versus-host disease are warranted. 相似文献